- Q1 2024 Bergenbio ASA Earnings Call TranscriptMay 29, 2024kr14.28 (-1.11%)Earnings
- Q3 2023 Bergenbio ASA Earnings Call TranscriptNov 14, 2023kr18.38 (+1.32%)Earnings
- Q2 2023 Bergenbio ASA Earnings Call TranscriptAug 23, 2023kr11.06 (-11.52%)Earnings
- Q4 2022 Bergenbio ASA Earnings Call TranscriptFeb 16, 2023kr625.94 (+2.84%)Earnings
- Q3 2022 Bergenbio ASA Earnings Call TranscriptNov 15, 2022kr661.34 (-1.73%)Earnings
- Q2 2022 Bergenbio ASA Earnings Call TranscriptAug 23, 2022kr1029.14 (-7.17%)Earnings
- Q1 2022 Bergenbio ASA Earnings Call TranscriptMay 24, 2022kr1342.54 (-5.76%)Earnings
- Bergenbio ASA Strategy Update TranscriptMay 04, 2022
- Q4 2021 Bergenbio ASA Earnings Call TranscriptFeb 16, 2022kr1486.73 (-4.44%)Earnings
- Q3 2021 Bergenbio ASA Earnings Call TranscriptNov 16, 2021kr1723.29 (-0.99%)Earnings
- Q2 2021 Bergenbio ASA Earnings Call TranscriptAug 17, 2021kr1944.31 (-3.68%)Earnings
- Q1 2021 Bergenbio ASA Earnings Call TranscriptMay 19, 2021kr2020.29 (-9.09%)Earnings
- Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call TranscriptMay 18, 2021
- Q4 2020 Bergenbio ASA Earnings Call TranscriptFeb 10, 2021kr2823.23 (-6.30%)Earnings
- Q3 2020 Bergenbio ASA Earnings Call TranscriptNov 17, 2020kr2413.12 (-3.95%)Earnings
- Q2 2020 Bergenbio ASA Earnings Call TranscriptAug 18, 2020kr3030.44 (-3.04%)Earnings
- Q1 2020 Bergenbio ASA Earnings Call TranscriptMay 19, 2020kr3436.22 (-7.01%)Earnings
- Q4 2019 Bergenbio ASA Earnings Call TranscriptFeb 11, 2020kr1653.92 (+11.37%)Earnings
Q2 2020 Bergenbio ASA Earnings Call Transcript
Hello. Good morning. Welcome to BerGenBio's quarter 2 half year report highlight 2020. My name is Richard Godfrey, I'm the CEO of BerGenBio. And I'm joined by Rune Skeie, our CFO; Hani Gabra, our Chief Medical Officer; and James Lorens, our Chief Scientific Officer.
I'd like to give a special welcome to our new shareholders. We have more than 10,000 shareholders in the company now, and I'd also like to extend a special welcome to new international shareholders that have recently joined our register.
Next slide, please. We are, of course, a public company, and I should draw your attention to these forward-looking statements and ask that you pay attention to the details.
Next slide, please, Slide 3. By way of a corporate overview and introduction, BerGenBio is a world leader in understanding the role and function of AXL biology. AXL is a tyrosine kinase that drives aggressive disease including immune-evasion, therapy-resistant and metastatic cancer, fibrosis and also viral infections. BerGenBio has a number of inhibitors of AXL in clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)